To include your compound in the COVID-19 Resource Center, submit it here.

Pfizer reports possible Remoxy delay

Pfizer Inc. (NYSE:PFE) disclosed in its 1Q11 conference call that the approval or launch of pain candidate Remoxy could be delayed by an undisclosed issue in the manufacturing section

Read the full 290 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE